Concepedia

Rapid Onset Formulation

Rapid Onset Formulation is a pharmaceutical dosage form designed to achieve therapeutic drug concentrations in the systemic circulation within minutes following administration, distinguished from other immediate-release systems by its optimized physicochemical and biopharmaceutical properties that enable significantly accelerated dissolution, disintegration, or absorption kinetics.

73

Publications

2.9K

Citations

309

Authors

135

Institutions

Publications per year

2017–2026

24

Parents

Publications

73

PET Study Examining Pharmacokinetics, Detection and Likeability, and Dopamine Transporter Receptor Occupancy of Short- and Long-Acting Oral Methylphenidate

Thomas Spencer, Joseph Biederman, Patrick E. Ciccone et al. · American Journal of Psychiatry · 2006 · 202 citations

, , +17

General theory of the plasmoid instability

Luca Comisso, Manasvi Lingam, Yi-Min Huang et al. · Physics of Plasmas · 2016 · 160 citations · Full text

, , +6

Formulation Design of Self-Microemulsifying Drug Delivery Systems for Improved Oral Bioavailability of Celecoxib

Subramanian Natesan, Subhabrata Ray, Saroj K. Ghosal et al. · Biological and Pharmaceutical Bulletin · 2004 · 159 citations · Full text

, , +17

A New Calcipotriol/Betamethasone Formulation with Rapid Onset of Action was Superior to Monotherapy with Betamethasone Dipropionate or Calcipotriol in Psoriasis Vulgaris

W.S. Douglas, Yves Poulin, J. Decroix et al. · Acta Dermato Venereologica · 2002 · 159 citations · Full text

, , +10

Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head‐to‐head, placebo‐controlled trial

Steven A. Kaplan, Tim Schneider, Jenelle E. Foote et al. · British Journal of Urology · 2010 · 99 citations

, , +17

1–5 of 73

Authors

309

  1. DC
    Daniela Cavalleri

    Elanco (United States), United States

    4 publications · 118 citations

    4

    h-index

  2. WS
    Wolfgang Seewald

    Novartis (Switzerland), Switzerland

    4 publications · 118 citations

    4

    h-index

  3. MM
    Martin Murphy

    Elanco (United States), United States

    4 publications · 118 citations

    4

    h-index

  4. SN
    Steve Nanchen

    Elanco (United States), United States

    4 publications · 118 citations

    4

    h-index

  5. JD
    Jason Drake

    Elanco (United States), United States

    3 publications · 65 citations

    3

    h-index

1–5 of 309

Institutions

135

  1. Elanco (United States)

    Greenfield, United States

    4 h-index

    4 publications

    118 citations

  2. Cairo University

    Giza, Egypt

    4 h-index

    6 publications

    94 citations

  3. Biodel (United States)

    Danbury, United States

    2 h-index

    10 publications

    382 citations

  4. Al-Azhar University

    Cairo, Egypt

    2 h-index

    3 publications

    80 citations

  5. King Abdulaziz University

    Jeddah, Saudi Arabia

    2 h-index

    6 publications

    297 citations

  6. Pfizer (United States)

    New York, United States

    2 h-index

    8 publications

    579 citations

  7. Assiut University

    Asyut, Egypt

    2 h-index

    2 publications

    39 citations

  8. Fayoum University

    Al Fayyum, Egypt

    2 h-index

    2 publications

    37 citations

1–8 of 135

Venues

  1. Drug Development and Industrial Pharmacy

    6 publications · 117 citations

    6

    h-index

  2. PubMed

    Repository · 4 publications · 64 citations

    4

    h-index

  3. Parasites & Vectors

    4 publications · 118 citations

    4

    h-index

  4. Drug Delivery

    3 publications · 68 citations

    3

    h-index

  5. Saudi Pharmaceutical Journal

    2 publications · 42 citations

    2

    h-index

1–5